Utilizing preclinical models to develop targeted therapies for rare central nervous system cancers

Patients with rare central nervous system (CNS) tumors typically have a poor prognosis and limited therapeutic options. Historically, these cancers have been difficult to study due to small number of patients. Recent technological advances have identified molecular drivers of some of these rare canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Arakaki, Aleena K S, Szulzewsky, Frank, Gilbert, Mark R, Gujral, Taranjit S, Holland, Eric C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Supplement Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561121/
https://www.ncbi.nlm.nih.gov/pubmed/34725698
http://dx.doi.org/10.1093/neuonc/noab183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561121/
https://www.ncbi.nlm.nih.gov/pubmed/34725698
http://dx.doi.org/10.1093/neuonc/noab183

Ejemplares similares